The circadian clock and the hypoxic response pathway in kidney cancer

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 1-7

  Mazzoccoli, Gianluigi ^a   De Cata, Angelo ^a   Piepoli, Ada ^a   Vinciguerra, Manlio ^a,b,c  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b Istituto Euro Mediterraneo di Scienza e Tecnologia (IEMEST)   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Circadian; Clock gene; Hypoxia; Kidney; Rhythm

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PER1 PROTEIN; PROTEIN BMAL1; PROTEIN P53; PROTEIN TIMELESS; RETINOID RELATED ORPHAN RECEPTOR ALPHA; TRANSCRIPTION FACTOR CLOCK; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

CARCINOGENESIS; CELL HYPOXIA; CELL MIGRATION; CELL PH; CELL SURVIVAL; CIRCADIAN RHYTHM; DISEASE COURSE; ENERGY METABOLISM; GENE EXPRESSION; GENE MUTATION; HOMEOSTASIS; HUMAN; KIDNEY CARCINOMA; LETHALITY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANOXIA; CARCINOMA, RENAL CELL; CIRCADIAN CLOCKS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84894475093     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1076-5     Document Type: Review

References (58)

1. Tang PA, Vickers MM, Heng DY. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. Hematol Oncol Clin North Am. 2011;25(4):871-91.
2. Dahinden C, Ingold B,Wild P, Boysen G, Luu VD, MontaniM, et al. Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res. 2010;16(1):88-98.
3. Frew IJ, Krek W. pVHL: a multipurpose adaptor protein. Sci Signal. 2008;1:e30.
4. Vanharanta S, ShuW, Brenet F, Hakimi AA, Heguy A, Viale A, et al. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med. 2013;19(1):50-6.
5. Semenza GL. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life. 2008;60(9):591-7.
6. Zhou J, Schmid T, Schnitzer S, Brune B. Tumor hypoxia and cancer progression. Cancer Lett. 2006;237(1):10-21.
7. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell. 2006;22:395-405.
8. Contractor H, ZariwalaM, Bugert P, Zeisler J,Kovacs G.Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. J Pathol. 1997;181:136-9.
9. KimM, Yan Y, Lee K, SgagiasM, Cowan KH. Ectopic expression of von Hippel-Lindau tumor suppressor induces apoptosis in 786-O renal cell carcinoma cells and regresses tumor growth of 786-O cells in nude mouse. Biochem Biophys Res Commun. 2004;320:945-50.
10. Pause A, Lee S, Lonergan KM, Klausner RD. The von Hippel- Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A. 1998;95:993-8.
11. Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 1999;9:125-8.
12. Sansal I, SellersWR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004;22:2954-63.
13. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, et al. PKB/ Aktmediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. NatMed. 2002;8(10):1145-52.
14. Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene. 1998;16(24):3215-8.
15. Shin Lee J, Seok Kim H, Bok Kim Y, Cheol Lee M, Soo PC. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol. 2003;84:166-72.
16. Mazzoccoli G. The timing clockwork of life. J Biol Regul Homeost Agents. 2011;25(1):137-43. Review.
17. Mazzoccoli G, Pazienza V, Vinciguerra M. Clock genes and clock controlled genes in the regulation of metabolic rhythms. Chronobiol Int. 2012;29(3):227-51.
18. Mazzoccoli G, Francavilla M, Giuliani F, Aucella F, Vinciguerra M, Pazienza V, et al. Clock gene expression in mouse kidney and testis: analysis of periodical and dynamical patterns. J Biol Regul Homeost Agents. 2012;26(2):303-11.
19. Mazzoccoli G, Cai Y, Liu S, Francavilla M, Giuliani F, Piepoli A, et al. REV-ERBalpha and the clock gene machinery in mouse peripheral tissues: a possible role as a synchronizing hinge. J Biol Regul Homeost Agents. 2012;26(2):265-76.
20. Mazzoccoli G, Sothern RB, Greco G, Pazienza V, VinciguerraM, Liu S, et al. Time-related dynamics of variation in core clock gene expression levels in tissues relevant to the immune system. Int J Immunopathol Pharmacol. 2011;24(4):869-79.
21. Cho H, Zhao X, Hatori M, Yu RT, Barish GD, Lam MT, et al. Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β. Nature. 2012;485(7396):123-7.
22. Ghorbel MT, Coulson JM, Murphy D. Cross-talk between hypoxic and circadian pathways: cooperative roles for hypoxia-inducible factor 1alpha and CLOCK in transcriptional activation of the vasopressin gene. Mol Cell Neurosci. 2003;22(3):396-404.
23. Chilov D, Hofer T, Bauer C, Wenger RH, Gassmann M. Hypoxia affects expression of circadian genes PER1 and CLOCK in mouse brain. FASEB J. 2001;15:2613-22.
24. Hogenesch JB, Gu YZ, Moran SM, Shimomura K, Radcliffe LA, Takahashi JS, et al. The basic helix-loop-helix-PAS protein MOP9 is a brain-specific heterodimeric partner of circadian and hypoxia factors. J Neurosci. 2000;20(13):RC83.
25. Kim EJ, Yoo YG, Yang WK, Lim YS, Na TY, Lee IK, et al. Transcriptional activation of HIF-1 by RORalpha and its role in hypoxia signaling. Arterioscler Thromb Vasc Biol. 2008;28(10):1796-802.
26. Agostino PV, Harrington ME, Ralph MR, Golombek DA. Casein kinase-1-epsilon (CK1epsilon) and circadian photic responses in hamsters. Chronobiol Int. 2009;26:126-33.
27. Mottet D, Ruys SP, Demazy C, Raes M, Michiels C. Role for casein kinase 2 in the regulation of HIF-1 activity. Int J Cancer. 2005;117(5):764-74.
28. Kalousi A, Mylonis I, Politou AS, Chachami G, Paraskeva E, Simos G. Casein kinase 1 regulates human hypoxia-inducible factor HIF-1. J Cell Sci. 2010;123(Pt 17):2976-86.
29. Fang Z, Carlson SH, Peng N,Wyss JM. Circadian rhythm of plasma sodium is disrupted in spontaneously hypertensive rats fed a high-NaCl diet. Am J Physiol Regul Integr Comp Physiol. 2000;278:R1490-5.
30. Yamamoto T, Nakahata Y, Soma H, AkashiM,Mamine T, Takumi T. Transcriptional oscillation of canonical clock genes in mouse peripheral tissues. BMC Mol Biol. 2004;9:5-18.
31. Saifur Rohman M, Emoto N, Nonaka H, Okura R, Nishimura M, Yagita K, et al. Circadian clock genes directly regulate expression of the Na(+)/H(+) exchanger NHE3 in the kidney. Kidney Int. 2005;67:1410-9.
32. Mazzoccoli G, Pazienza V, Panza A, Valvano MR, Benegiamo G, VinciguerraM, et al. ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. J Cancer Res Clin Oncol. 2012;138(3):501-11.
33. Pazienza V, Piepoli A, Panza A, Valvano MR, Benegiamo G, Vinciguerra M, et al. SIRT1 and the clock gene machinery in colorectal cancer. Cancer Invest. 2012;30(2):98-105.
34. Mazzoccoli G, Panza A, Valvano MR, Palumbo O, Carella M, Pazienza V, et al. Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int. 2011;28(10):841-51.
35. Hunt T, Sassone-Corsi P. Riding tandem: circadian clocks and the cell cycle. Cell. 2007;129:461-4.
36. Chen-Goodspeed M, Lee CC. Tumor suppression and circadian function. J Biol Rhythms. 2007;22:291-8.
37. Lee CC. Tumor suppression by the mammalian period genes. Cancer Causes Control. 2006;17:525-30.
38. Mullenders J, Fabius AW, Madiredjo M, Bernards R, Beijersbergen RL. A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One. 2009;4(3):e4798.
39. Gréchez-Cassiau A, Rayet B, Guillaumond F, Teboul M, Delaunay F. The circadian clock component BMAL1 is a critical regulator of p21WAF1/CIP1 expression and hepatocyte proliferation. J Biol Chem. 2008;283(8):4535-42.
40. Smith KD, Fu MA, Brown EJ. Tim-Tipin dysfunction creates an indispensible reliance on the ATR-Chk1 pathway for continued DNA synthesis. J Cell Biol. 2009;187(1):15-23.
41. Mailand N, Falck J, Lukas C, Syljuâsen RG, Welcker M, Bartek J, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science. 2000;288(5470):1425-9.
42. Montagnoli A, Valsasina B, Brotherton D, Troiani S, Rainoldi S, Tenca P, et al. Identification of Mcm2 phosphorylation sites by Sphase- regulating kinases. J Biol Chem. 2006;281(15):10281-90.
43. Fallone F, Britton S,Nieto L, Salles B,Muller C.ATR controls cellular adaptation to hypoxia through positive regulation of hypoxiainducible factor 1 (HIF-1) expression. Oncogene. 2012. doi:10.1038/ onc.2012.462.
44. Martin L, RaineyM, Santocanale C, Gardner LB. Hypoxic activation of ATR and the suppression of the initiation of DNA replication through cdc6 degradation. Oncogene. 2012;31:4076-84.
45. Honma S, Kawamoto T, Takagi Y, Fujimoto K, Sato F, Noshiro M, et al. Dec1 and Dec2 are regulators of the mammalian molecular clock. Nature. 2002;419(6909):841-4.
46. Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A, Lerman MI. Regulation of stra13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway. J Biol Chem. 2001;276:15306-15.
47. Koyanagi S, Kuramoto Y, Nakagawa H, Aramaki H, Ohdo S, Soeda S, et al.Amolecularmechanismregulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res. 2003;63:7277-83.
48. Jia YF, Xiao DJ, Ma XL, Song YY, Hu R, Kong Y, et al. Differentiated embryonic chondrocyte-expressed gene 1 is associated with hypoxia-inducible factor 1α and Ki67 in human gastric cancer. Diagn Pathol. 2013;8:37.
49. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604-13.
50. Falasca M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des. 2010;16(12):1410-6.
51. Maffucci T, Raimondi C, Abu-Hayyeh S, Dominguez V, Sala G, Zachary I, et al. A phosphoinositide 3-kinase/phospholipase Cgamma1 pathway regulates fibroblast growth factor-induced capillary tube formation. PLoS One. 2009;4(12):e8285.
52. Mazzoccoli G, Piepoli A, Carella M, Panza A, Pazienza V, Benegiamo G, et al. Altered expression of the clock gene machinery in kidney cancer patients. Biomed Pharmacother. 2012;66(3):175-9.
53. Wagner B, Patard JJ,Méjean A, Bensalah K, Verhoest G, Zigeuner R, et al. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol. 2009;55(2):452-9.
54. Martínez-Salamanca JI, Huang WC, Millán I, Bertini R, Bianco FJ, Carballido JA, et al. International renal cell carcinoma-venous thrombus consortium. prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol. 2011;59(1):120-7.
55. Oishi K. Plasminogen activator inhibitor-1 and the circadian clock in metabolic disorders. Clin Exp Hypertens. 2009;31(3):208-19. Review.
56. Maemura K, de la Monte SM, Chin MT, Layne MD, Hsieh CM, Yet SF, et al. CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J Biol Chem. 2000;275(47):36847-51.
57. Schoenhard JA, Smith LH, Painter CA, Eren M, Johnson CH, Vaughan DE. Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2. J Mol Cell Cardiol. 2003;35(5):473-81.
58. Oishi K, Miyazaki K, Uchida D, Ohkura N,Wakabayashi M, Doi R, et al. PERIOD2 is a circadian negative regulator of PAI-1 gene expression in mice. J Mol Cell Cardiol. 2009;46(4):545-52.